TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

[1] Tachimori Y(2019)Comprehensive registry of esophageal cancer in Japan, 2012 Esophagus 16 221-245

[2] Ozawa S(2004)Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516) Jpn J Clin Oncol 34 615-619

[3] Numasaki H(1999)Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus J Clin Oncol 17 2915-2921

[4] Ishihara R(2015)Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) Cancer Sci 106 407-412

[5] Matsubara H(2019)Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study J Clin Oncol 37 2-695

[6] Muro K(2014)Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice J Clin Invest 124 687-5468

[7] Ishida K(2014)Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade Cancer Res 74 5458-355

[8] Ando N(2015)Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen Cancer Immunol Res 3 345-619

[9] Yamamoto S(2015)PD-1 restrains radiotherapy-induced abscopal effect Cancer Immunol Res 3 610-931

[10] Ide H(2012)Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 925-1396

[1] Tachimori Y(2019)Comprehensive registry of esophageal cancer in Japan, 2012 Esophagus 16 221-245

[2] Ozawa S(2004)Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516) Jpn J Clin Oncol 34 615-619

[3] Numasaki H(1999)Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus J Clin Oncol 17 2915-2921

[4] Ishihara R(2015)Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) Cancer Sci 106 407-412

[5] Matsubara H(2019)Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study J Clin Oncol 37 2-695

[6] Muro K(2014)Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice J Clin Invest 124 687-5468

[7] Ishida K(2014)Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade Cancer Res 74 5458-355

[8] Ando N(2015)Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen Cancer Immunol Res 3 345-619

[9] Yamamoto S(2015)PD-1 restrains radiotherapy-induced abscopal effect Cancer Immunol Res 3 610-931

[10] Ide H(2012)Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 925-1396